Loading
Life sciences · Journal article
Экспериментальная И Клиническая Гастроэнтерология · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aim: To identify predictors for early liver fibrosis in patients with metabolically associated steatotic liver disease (MASLD). Materials and methods: A prospective cohort study included 131 patients with MASLD (77 females, 54 males; mean age 48.5 ± 0.95 years). Fibrosis stages were verified using transient elastography (FibroScan). Patients were divided into two groups: those without fibrosis (F0, n = 91) and those with early fibrosis (F1-F2, n = 40). Statistical analysis was performed using R (v. 4.3.3) with binary logistic regression and ROC analysis. Results: Early fibrosis was identified in 30.1% of the participants. Type 2 diabetes mellitus (OR = 12.0; 95% CI: 3.94-36.53), a positive family history (OR = 7.75), and hyperlipidemia (OR = 5.77) were established as key risk factors. Obesity (BMI > 30 kg/m²) acted as an obligatory prerequisite for the presence of fibrosis. The most significant quantitative predictors were glycemia level (OR = 2.34) and HOMA-IR index (OR = 1.89). According to the ROC analysis, AST (AUC = 0.832, threshold > 48.5 U/L) and glycemia level (AUC = 0.826, threshold > 7.05 mmol/L) showed the highest diagnostic accuracy. The developed predictive model based on metabolic factors demonstrated high accuracy (AUC = 0.902; sensitivity - 82.5%, specificity - 83.5%), significantly outperforming the international NFS (AUC = 0.829) and FIB-4 (AUC = 0.617) indices. Conclusion: The inclusion of metabolic parameters in the developed algorithm allows for high-accuracy prediction of early changes in liver tissue, making the model an effective screening tool for primary healthcare.